Neurocard
Neurocard: instructions for use and reviews
- 1. Release form and composition
- 2. Pharmacological properties
- 3. Indications for use
- 4. Contraindications
- 5. Method of application and dosage
- 6. Side effects
- 7. Overdose
- 8. Special instructions
- 9. Application during pregnancy and lactation
- 10. Use in childhood
- 11. In case of impaired renal function
- 12. For violations of liver function
- 13. Drug interactions
- 14. Analogs
- 15. Terms and conditions of storage
- 16. Terms of dispensing from pharmacies
- 17. Reviews
- 18. Price in pharmacies
Latin name: Neurocard
ATX code: N07XX
Active ingredient: Ethylmethylhydroxypyridine succinate (Ethylmethylhydroxypyridine succinate)
Producer: FKP "Kursk Biofabrika - firm" BIOC "(Russia)
Description and photo update: 09.10.2019
Neurocard is an antioxidant drug for the treatment of pathologies of the nervous system.
Release form and composition
Dosage form - solution for intravenous (i / v) and intramuscular (i / m) administration: colorless or slightly colored with a yellowish, brownish-yellowish or reddish tint, transparent (in a cardboard box 1 or 2 cell contour packages in which 5 ampoules made of light-shielding / neutral glass containing 2 or 5 ml of solution, complete with an ampoule knife / scarifier and instructions for using Neurocard).
Composition of 1 ml solution for i / v and i / m administration:
- active substance: ethylmethylhydroxypyridine succinate - 50 mg;
- auxiliary component: water for injection - up to 1 ml.
Pharmacological properties
Pharmacodynamics
Neurocard has anxiolytic, anticonvulsant, stress-protective, nootropic, membrane-stabilizing, antihypoxic and antioxidant effects. The drug belongs to the class of 3-hydroxypyridines.
Pharmacological properties of Neurocard, due to the effectiveness of its active substance - ethylmethylhydroxypyridine succinate:
- inhibition of lipid peroxidation processes;
- increased activity of the antioxidant enzyme system;
- restoration of the damaged structure and function of membranes;
- modeling effect on ion channels;
- transport of neurotransmitters;
- improved synaptic transmission;
- increasing the body's resistance to the influence of various damaging factors [intoxication with antipsychotic drugs (neuroleptics) or alcohol, cerebrovascular accident, trauma, ischemia, hypoxia, shock] through the activation of energy-synthesizing functions of mitochondria and improvement of energy metabolism in the cell;
- decrease in the content of low-density lipoproteins and total cholesterol (hypolipidemic effect);
- increased compensatory activation of aerobic glycolysis and a decrease in the degree of inhibition of oxidative processes in the Krebs cycle during hypoxia with an increase in creatine phosphate and adenosine triphosphate;
- activation of the energy-synthesizing function of mitochondria;
- inhibition of free radical processes of lipid peroxidation - activation of superoxide oxidase; influencing the physicochemical properties of the membrane; increasing the content of polar fractions of phospholipids (for example, phosphatidylinositol, phosphatidylserine) in the membrane; decrease in the ratio of cholesterol / phospholipids; an increase in membrane fluidity and a decrease in the viscosity of the lipid layer; activation of energy-synthesizing functions of mitochondria and improvement of energy metabolism in the cell and, as a consequence, protection of the cell apparatus and the structure of cytoplasmic membranes;
- change in the functional activity of the biological membrane, due to which conformational changes in protein macromolecules of synaptic membranes occur. As a result, Neurocard has a modulating effect on the activity of receptor complexes (including acetylcholine, benzodiazepine and gamma-aminobutyric acid), ion channels and membrane-bound enzymes by increasing the activity of neurotransmitters, activating synaptic processes and enhancing their ability to bind to ligands.
Pharmacokinetics
The maximum concentration in blood plasma (C max) of ethylmethylhydroxypyridine succinate with a single and course administration is achieved after 58 minutes after administration.
C max with Neurocard injections at a dose of 400-500 mg varies from 0.0035 to 0.004 mg per ml. The distribution of the substance in tissues and organs is fast. Its retention time is from 0.7 to 1.3 hours, at the same time, it is rapidly excreted from the blood plasma and is almost not detected in it after 4 hours.
In cases of single or continuous administration of the drug, the pharmacokinetic profiles do not differ significantly. Its metabolism takes place in the liver by glucuronidation.
Five metabolites of ethylmethylhydroxypyridine succinate have been identified, namely:
- 1st metabolite - 3-hydroxypyridine phosphate: formed in the liver. Under the influence of alkaline phosphatase in the blood, it breaks down into 3-hydroxypyridine and phosphoric acid;
- 2nd metabolite: pharmacologically active, it is formed in large quantities and is found in the urine for 1–2 days after administration of the solution;
- 3rd metabolite: excreted in large quantities in the urine;
- 4th and 5th metabolites: are glucurone conjugates.
Excretion of Neurocard is carried out in the urine unchanged and in the form of glucuron conjugates.
Indications for use
- vegetative dystonia syndrome;
- chronic cerebral ischemia;
- traumatic brain injury and its consequences;
- acute violation of cerebral circulation;
- anxiety disorders against the background of neurotic and neurosis-like conditions;
- primary open-angle glaucoma of various stages (as part of complex therapy);
- encephalopathy;
- mild cognitive disorders of atherosclerotic origin;
- acute necrotizing pancreatitis;
- acute myocardial infarction (as part of complex treatment);
- withdrawal syndrome in alcoholism with a predominance of vegetative-vascular and neurosis-like disorders in the clinical picture (for relief);
- acute intoxication with antipsychotic drugs.
Contraindications
Absolute:
- acute renal and liver dysfunction;
- pregnancy;
- period of breastfeeding;
- children under the age of 18;
- individual intolerance to the components of the drug.
Neurocard is prescribed with caution, under medical supervision, to patients with a history of allergic pathologies.
Neurocard, instructions for use: method and dosage
Neurocard solution in ampoules is injected in / in a stream or drip or in / m. For infusion administration, it is diluted in isotonic sodium chloride solution. The injection of the drug is carried out slowly over a period of 5 to 7 minutes; drip - at a rate of 40 to 60 drops per minute.
The maximum dose of Neurocard should not exceed 1.2 g.
Recommended dosage regimen:
- acute disorders of cerebral circulation: in the first 10-14 days - 0.2-0.5 g of solution 2 to 4 times a day, intravenous drip; then for 14 days - 0.2-0.5 g of the drug 2-3 times a day / m;
- traumatic brain injury and its consequences: for 10-15 days, 0.2-0.5 g of solution 2 to 4 times a day, intravenous drip;
- chronic cerebral ischemia in the stage of decompensation: during the period from 10 to 14 days, 0.2–0.5 g of Neurocard 1-2 times a day by intravenous drip or jet; then for 14 days, 0.1–0.25 g per day IM;
- chronic ischemia: for 10-14 days, 0.2-0.25 g of the drug 2 times a day / m;
- syndrome of vegetative dystonia: for 14 days, 0.05–0.4 g per day IM;
- mild cognitive impairment in elderly patients against the background of anxiety disorders: during the period from 14 to 30 days, 0.1–0.3 g per day IM;
- dyscirculatory encephalopathy in the phase of decompensation: for 14 days, 0.2-0.5 g of the drug 1-2 times a day intravenous drip or jet; then, within 14 days, 0.1–0.25 g per day IM;
- course prevention of discirculatory encephalopathy: within 10-14 days, 0.2-0.25 g 2 times a day, IM;
- acute myocardial infarction (as part of complex therapy): against the background of traditional treatment of pathology, which includes the use of antiplatelet and anticoagulant drugs, thrombolytics, angiotensin-converting enzyme inhibitors, beta-blockers and nitrates, as well as symptomatic drugs, according to indications, Neurocard is used for 14 days per / in or in / m (in the first 5 days - in / in, in the next 9 days - in / m). The drug is administered intravenously by slow drip infusion over a period of 30 to 90 minutes; to it add 0.1-0.15 liters of 5% dextrose / glucose solution or 0.9% sodium chloride solution. Slow jet intravenous administration of the drug is allowed for 5 minutes (at least) if necessary. The frequency of administration of the solution is 3 times a day, an interval of 8 hours is observed between injections. The daily dose is set based on the calculation - 0.006-0.009 g of Neurocard per 1 kg of body weight. The maximum single dose should not exceed 0.25 g per day, daily - 0.8 g;
- open-angle glaucoma of various stages (as part of complex therapy): for 14 days, 0.1–0.3 g from 1 to 3 times a day, IM;
- alcohol withdrawal syndrome: within 5-7 days, 0.2-0.5 g of solution 2-3 times a day intravenously or intramuscularly;
- acute intoxication with antipsychotic drugs: for 7-14 days, 0.2-0.5 g of the drug per day i / v;
- peritonitis, acute necrotizing pancreatitis (acute purulent-inflammatory processes of the abdominal cavity): on the first day Neurocard is used both in the preoperative and postoperative periods. The dosage is set individually, depending on the form and severity of the pathology, process and clinical course options. The drug is canceled gradually and only after achieving a stable positive clinical and laboratory effect;
- acute edematous (interstitial) pancreatitis: 0.2–0.5 g of the drug 3 times a day intravenous drip (after adding to isotonic sodium chloride solution) and intramuscularly;
- mild severity of necrotizing pancreatitis; 0.1–0.2 g of Neurocard 3 times a day i / v drip (after adding to isotonic sodium chloride solution) and i / m; moderate severity - 0.2 g of the product 3 times a day i / v drip (after adding sodium chloride to isotonic solution); severe course - on the first day in the pulse dosage, 0.8 g of the solution is injected, with a double mode of administration, then - 0.2-0.5 g of the agent 2 times a day, gradually reducing the daily dose; extremely severe course - an initial dose of 0.8 g per day is administered until persistent relief of the manifestations of pancreatogenic shock is achieved, to stabilize the state - 0.3-0.5 g of the agent 2 times a day intravenous drip (after adding sodium chloride to isotonic solution) gradually reducing the daily dosage.
Side effects
Against the background of therapy with Neurocard, the following undesirable effects may develop:
- allergic reactions, a feeling of spreading heat throughout the body, chest discomfort and sore throat, an unpleasant odor, a metallic taste or dry mouth, a feeling of lack of air - usually associated with an excessively high injection rate and are short-lived;
- nausea, flatulence, sleep disturbances (problems with falling asleep or drowsiness) - most often as a result of prolonged use of Neurocard;
- short-term increase in blood pressure.
Overdose
The main symptoms of an ethylmethylhydroxypyridine succinate overdose: insomnia or drowsiness (sleep disturbance); with intravenous administration - a short-term and insignificant increase in blood pressure (from 1.5 to 2 hours).
Usually, therapy is not required, the manifestations disappear within 1 day on their own. In severe cases, sleeping pills are prescribed to treat insomnia. With an excessive increase in blood pressure, antihypertensive drugs are used under the control of blood pressure.
special instructions
In patients with bronchial asthma against the background of individual intolerance to sulfites, in some cases (especially in susceptible individuals), severe hypersensitivity reactions may develop.
Ethylmethylhydroxypyridine succinate enhances the effect of anticonvulsant and tranquilizing drugs, which is why, when using such combinations, it may be necessary to adjust the doses of the corresponding drugs.
Influence on the ability to drive vehicles and complex mechanisms
At the beginning of treatment with Neurocard, patients are advised to refrain from performing work that requires the speed of psychomotor reactions and high concentration of attention, including from driving vehicles and complex mechanisms.
Application during pregnancy and lactation
Neurocard is not prescribed during pregnancy / lactation, since there have been no strictly controlled clinical studies of the safety of using the drug in such cases.
Pediatric use
Neurocard is not prescribed to patients under 18 years of age, since the safety and efficacy of the drug in patients of this age group have not been established.
With impaired renal function
In acute renal dysfunction, Neurocard is contraindicated.
For violations of liver function
Neurocard is not used in patients with acute liver dysfunction.
Drug interactions
Possible interactions of ethylmethylhydroxypyridine succinate with other medicinal substances / preparations:
- antiparkinsonian drugs (levodopa), tranquilizers (diazepam, phenazepam), anticonvulsants (carbamazepine), nitrate-containing drugs: Neurocard enhances their action;
- ethyl alcohol: there is a decrease in its toxic effects.
Analogs
Neurocard analogs are Meksiprim, Astrox, Meksidant, Cerecard, Metostabil, Meksikor, Meksidol, Proinin, MetutsinVel, Medomeksi, Neyroks, Meksifin, Meksilek-Lekpharm.
Terms and conditions of storage
Store in a place protected from light and moisture at temperatures up to 25 ° C. Keep out of the reach of children.
The shelf life is 3 years.
Terms of dispensing from pharmacies
Dispensed by prescription.
Reviews about Neurocard
According to reviews, Neurocard is a safe, affordable and effective drug used to treat pathologies of the nervous system, the use of which does not cause side effects.
Price for Neurocard in pharmacies
The price of Neurocard in ampoules is unknown, since the drug is not available in pharmacies.
The approximate cost of analogs:
- Cerecard (10 ampoules in a package containing 2 ml of solution for intravenous and intramuscular administration) - 163 rubles;
- Mexicor (in a package of 5 ampoules containing 5 ml of solution for intravenous and intravenous administration) - 212 rubles;
- Neurox (in a package of 5 ampoules containing 5 ml of solution for intravenous and intramuscular administration) - 263 rubles.
Anna Kozlova Medical journalist About the author
Education: Rostov State Medical University, specialty "General Medicine".
Information about the drug is generalized, provided for informational purposes only and does not replace the official instructions. Self-medication is hazardous to health!
